Open an account

Oncternal Therapeutics

ONCT · NASDAQ

$0.5266−$0.1673 (−24.11%)TodayMarket closed ·
No price history for this range.

About ONCT

Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.

Employees
29
Headquarters
San Diego, California
Listed
Feb 3, 2004
Sector
Health Care
Industry
Biotechnology
Website
oncternal.com

ONCT key statistics

Market cap
1.56M
Price-earnings ratio
—
Dividend yield
—
Average volume
108.34K
Volume
702.15K
Open price
$0.70
High today
$0.70
Low today
$0.5266
52 Week high
$1.33
52 Week low
$0.2625

Oncternal Therapeutics (ONCT) at a glance

As of Dec 2, 2024, Oncternal Therapeutics (ONCT) shares are priced at $0.5266, giving the company a market cap of 1.56M.

Today the stock has traded between $0.5266 and $0.70. The current price is 0.0% above the day's low and 24.8% below its high.

Volume so far is 702.15K shares, above the average of 108.34K shares a day.

Over the past year Oncternal Therapeutics has ranged from $0.2625 to $1.33, and now sits 25% of the way up that range.

Oncternal Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q3 FY24 it reported -$2.86 per share against an estimate of -$3.26.

ONCT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 6.1% on average.

  1. Q4 FY22: reported -$4.00 per share against an estimate of -$4.25
  2. Q1 FY23: reported -$4.00 per share against an estimate of -$4.15
  3. Q2 FY23: reported -$3.00 per share against an estimate of -$3.26
  4. Q3 FY23: reported -$3.40 per share against an estimate of -$2.96
  5. Q4 FY23: reported -$3.11 per share against an estimate of -$3.13
  6. Q1 FY24: reported -$2.83 per share against an estimate of -$2.94
  7. Q2 FY24: reported -$2.89 per share against an estimate of -$3.17
  8. Q3 FY24: reported -$2.86 per share against an estimate of -$3.26

ONCT news

  • Press releaseBusiness Wire

    Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

  • Press releaseBusiness Wire

    Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Avi Kapoor

    Gold Down Over 3%; Rigetti Computing Shares Spike Higher

  • Avi Kapoor

    Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October

  • Avi Kapoor

    Dow Surges Over 300 Points; Bath & Body Works Posts Upbeat Earnings

  • Avi Kapoor

    Dow Surges Over 100 Points; ModivCare Shares Plummet

  • Avi Kapoor

    Crude Oil Surges 3%; Kroger Posts Upbeat Earnings

Similar companies

Companies in the same industry as Oncternal Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.